APA (7th ed.) Citation

Cortes, J., & Schneeweiss, A. (2015). Afatinib alone or afatinib plus vinorelbine versus investigator’s choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): A randomised, open-label, multicentre, phase 2 trial. The lancet. Oncology, 16(16), . https://doi.org/10.1016/S1470-2045(15)00373-3

Chicago Style (17th ed.) Citation

Cortes, Javier, and Andreas Schneeweiss. "Afatinib Alone or Afatinib Plus Vinorelbine Versus Investigator’s Choice of Treatment for HER2-positive Breast Cancer with Progressive Brain Metastases After Trastuzumab, Lapatinib, or Both (LUX-Breast 3): A Randomised, Open-label, Multicentre, Phase 2 Trial." The Lancet. Oncology 16, no. 16 (2015). https://doi.org/10.1016/S1470-2045(15)00373-3.

MLA (9th ed.) Citation

Cortes, Javier, and Andreas Schneeweiss. "Afatinib Alone or Afatinib Plus Vinorelbine Versus Investigator’s Choice of Treatment for HER2-positive Breast Cancer with Progressive Brain Metastases After Trastuzumab, Lapatinib, or Both (LUX-Breast 3): A Randomised, Open-label, Multicentre, Phase 2 Trial." The Lancet. Oncology, vol. 16, no. 16, 2015, https://doi.org/10.1016/S1470-2045(15)00373-3.